Red Tree Venture Capital

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Creating novel bispecific antibodies that activate the immune system to fight cancer

Magnus Medical develops a closed-loop neuromodulation technology to effectively treat intractable neurological and psychiatric disorders.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Ceribell, Inc. specializes in the design and manufacture of medical devices aimed at acquiring and interpreting electroencephalography (EEG) data for patients with neurological conditions. The company offers the Ceribell EEG System, which includes a versatile EEG headband accommodating various hair types and head sizes, and a compact, battery-operated EEG recorder that delivers clinical-quality data with an on-device display. Ceribell focuses on improving the accessibility and efficiency of EEG technology by developing an FDA-cleared instant EEG system that can be set up by any healthcare provider in just six minutes, eliminating the need for specialized technologists. This system features a unique Brain Stethoscope function that converts brainwaves into sound, allowing for the detection of seizures through auditory means. By facilitating earlier diagnoses and targeted treatments for seizures, including non-convulsive seizures, Ceribell aims to enhance patient outcomes while reducing risks such as mortality and complications. Founded in 2014 and based in Mountain View, California, Ceribell is committed to transforming the diagnosis and management of serious neurological conditions in acute care settings.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.